Contact Us
Drug Search Results
More Filters [+]

Lamivudine

Alternative Names: lamivudine, epivir, zeffix, lamivudin, epivir-hbv, lamivudina, delstrigo, dovato, triumeq, cimduo, symfi, temixys, trizivir, symfi lo, dutrebis, triumeq pd
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Lamivudine (Epivir-HBV) is used to treat hepatitis B infection. Lamivudine is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV and hepatitis B in the blood. (Sourced from: https://medlineplus.gov/druginfo/meds/a696011.html)

Mechanisms of Action: NRT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: HIV Infections | Hepatitis | Hepatitis, Chronic | Inflammation | Hepatitis B | Hepatitis B, Chronic | HIV Infections | HIV Infections | HIV Infections | HIV Infections | HIV Infections

Known Adverse Events: Headache | Diarrhea | Dizziness | Insomnia | Depressive Disorder | Pain Unspecified

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lamivudine

Countries in Clinic: Argentina, Belgium, Brazil, Burkina Faso, Cameroon, Canada, Chile, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Ivory Coast, Japan, Mexico, Poland, Portugal, Puerto Rico, Spain, Sweden, Switzerland, United Kingdom, United States

Active Clinical Trial Count: 15

Highest Development Phases

Phase 3: HIV Infections|Hepatitis B, Chronic|Tuberculosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
DOVETAIL

P3

Not yet recruiting

Tuberculosis

2028-01-31

219816

P3

Unknown Status

HIV Infections

2026-12-09

219700

P3

Unknown Status

HIV Infections

2026-08-25

VOGUE

P3

Recruiting

HIV Infections

2025-11-03

Recent News Events

Date

Type

Title

12/19/2024

News Article

 Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection

11/07/2024

News Article

 Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic

11/07/2024

News Article

 ViiV Healthcare expands on real-world data supporting use of long-acting therapies in diverse patient populations at HIV Glasgow

09/04/2024

News Article

 Hepatitis Therapeutics Market Size worth USD 21.9 Billion by 2031, with a CAGR of 3.6% - Transparency Market Research, Inc.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions